Zota Health Care LImited — Important, 26-11-2024: Updates

Zota Health Care Limited has secured a product registration license for S-AMLOZED 5 in Myanmar, a calcium channel blocker containing 5mg of S-Amlodipine. The license, granted by Myanmar's Ministry of Health Department of Food and Drug Administration, is valid for five years with an option for renewal. The company plans to commence exports of this product to Myanmar in the near term. This development could signal positive growth opportunities for Zota in the Southeast Asian market, allowing them to broaden their product reach and enhance revenue streams. Investors should watch closely for the execution of these plans and potential impacts on the company’s financial performance.